AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30317532 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS (2000 pulses, 20 Hz at 100% rMT for 10 days)
Number of subjects: 26
Study 30317532 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 26
Study 30317532 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 26
Study 30004916 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mononuclear cells (BM-MNCs) injected intramuscularly at 40 locations of the calf muscle (500-700 mL harvested, 40 mL concentrated).
Number of subjects: 54
Study 30004916 — intervention group
Group type: COMPARATOR
Intervention: Placebo (diluted blood) injected intramuscularly at 40 locations of the calf muscle.
Number of subjects: 54
Study 26613203 — intervention group
Group type: EXPERIMENTAL
Intervention: PCBMT (4-session program adapted from mindfulness-based stress reduction)
Number of subjects: 62
Study 26613203 — intervention group
Group type: COMPARATOR
Intervention: PC treatment as usual (control group)
Number of subjects: 62
Study 25138064 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose almonds (50-100 g/d)
Number of subjects: 27
Study 25138064 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose almonds with half-dose muffins
Number of subjects: 27
Study 25138064 — intervention group
Group type: COMPARATOR
Intervention: Full-dose muffins
Number of subjects: 27
Study 22762147 — intervention group
Group type: EXPERIMENTAL
Intervention: NOMAC/E2 (2.5 mg/1.5 mg) in a 24/4‐day regimen (n= 56)
Number of subjects: 110
Study 22762147 — intervention group
Group type: COMPARATOR
Intervention: LNG/EE (150 μg/30 μg) in a 21/7‐day regimen (n= 54)
Number of subjects: 110
Study 20085939 — intervention group
Group type: EXPERIMENTAL
Intervention: sorafenib 400 mg twice daily
Number of subjects: 80
Study 20085939 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 80
Study 17333436 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (placebo-controlled trial)
Number of subjects: 553
Study 17333436 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient assessments of severity
Number of subjects: 553
Study 17333436 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI‐I and CGI‐I
Number of subjects: 553
Study 16279568 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast treatment
Number of subjects: 26
Study 16279568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 11870962 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive oral hygiene program (professional tooth cleaning, dental health information, and oral hygiene instruction) over a 6-month period
Number of subjects: 42
Study 11870962 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 42
Study 11870962 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive oral hygiene program
Number of subjects: 42
Study 11870962 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 11686668 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol treatment for 24 hours
Number of subjects: 20
Study 11686668 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy (HRT) with transdermal oestradiol and medroxyprogesterone for 6 weeks
Number of subjects: 20
Study 9621291 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum leptin levels in CRF patients
Number of subjects: 134
Study 9621291 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of body fat (assessed from skinfold measurements)
Number of subjects: 134
Study 9621291 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR
Number of subjects: 134
Study 9621291 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized leptin levels (leptin z-score)
Number of subjects: 134
Study 7930300 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 25 micrograms twice daily
Number of subjects: 0
Study 7930300 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 micrograms twice daily
Number of subjects: 0
Study 7930300 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 micrograms twice daily
Number of subjects: 0
Study 7930300 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (all doses)
Number of subjects: 0
Study 7930300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2467119 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg once daily
Number of subjects: 16
Study 2467119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30282584 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR-based classifier
Number of subjects: 151
Study 30282584 — intervention group
Group type: EXPERIMENTAL
Intervention: ACSP75 and ACSP-scores
Number of subjects: 151
Study 30282584 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD238-score
Number of subjects: 151
Study 30282584 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD273
Number of subjects: 151
Study 30282584 — intervention group
Group type: COMPARATOR
Intervention: Standard risk factors (age and GFR)
Number of subjects: 151
Study 27865696 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength Training (ST)
Number of subjects: 30
Study 27865696 — intervention group
Group type: COMPARATOR
Intervention: Stretch Control (SC)
Number of subjects: 30
Study 26230989 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture and Bee Venom Acupuncture (BVA)
Number of subjects: 11
Study 26230989 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 11
Study 24001247 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Frequency (NF) framing
Number of subjects: 325
Study 24001247 — intervention group
Group type: COMPARATOR
Intervention: Conditional Probability (CP) framing
Number of subjects: 325
Study 21925942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement appliance (Klearway - K or Silencer - S)
Number of subjects: 15
Study 18371542 — intervention group
Group type: EXPERIMENTAL
Intervention: CB + HB education program
Number of subjects: 132
Study 18371542 — intervention group
Group type: COMPARATOR
Intervention: CB education
Number of subjects: 132
Study 16634750 — intervention group
Group type: EXPERIMENTAL
Intervention: Color duplex sonography (CDS)
Number of subjects: 144
Study 16634750 — intervention group
Group type: COMPARATOR
Intervention: Phlebography
Number of subjects: 144
Study 14669926 — intervention group
Group type: EXPERIMENTAL
Intervention: deer antler velvet powder
Number of subjects: 38
Study 14669926 — intervention group
Group type: EXPERIMENTAL
Intervention: deer antler velvet extract
Number of subjects: 38
Study 14669926 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 38
Study 11089392 — intervention group
Group type: EXPERIMENTAL
Intervention: Best fitting mask (selected from different sizes and different brands)
Number of subjects: 20
Study 11089392 — intervention group
Group type: COMPARATOR
Intervention: Selected mask (only one brand but selected from different sizes)
Number of subjects: 20
Study 11089392 — intervention group
Group type: COMPARATOR
Intervention: Standard mask
Number of subjects: 20
Study 8867722 — intervention group
Group type: COMPARATOR
Intervention: Iron supplementation during pregnancy
Number of subjects: 7241
Study 8867722 — intervention group
Group type: COMPARATOR
Intervention: Placebo during pregnancy
Number of subjects: 7241
Study 8867722 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal contraception
Number of subjects: 7241
Study 8867722 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine devices
Number of subjects: 7241
Study 8867722 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood donation
Number of subjects: 7241
Study 8867722 — intervention group
Group type: COMPARATOR
Intervention: Non-blood donors
Number of subjects: 7241
Study 1628637 — intervention group
Group type: EXPERIMENTAL
Intervention: Total i.v. anaesthesia with propofol
Number of subjects: 60
Study 1628637 — intervention group
Group type: COMPARATOR
Intervention: Balanced volatile anaesthesia with enflurane
Number of subjects: 60
Study 29952698 — intervention group
Group type: EXPERIMENTAL
Intervention: Hop stabilization training (supervised exercises 3 times per week for 6 weeks)
Number of subjects: 28
Study 29952698 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 29952698 — intervention group
Group type: EXPERIMENTAL
Intervention: Hop stabilization training
Number of subjects: 28
Study 29952698 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 29128523 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette trial (participants smoked two cigarettes of their brand within 15min)
Number of subjects: 14
Study 29128523 — intervention group
Group type: COMPARATOR
Intervention: Sham trial (participants held the cigarette without lighting it)
Number of subjects: 14
Study 27187851 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise psychotherapy (UC-PT)
Number of subjects: 570
Study 27187851 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus one information session (UC-IS)
Number of subjects: 570
Study 25012727 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous pasireotide (300, 600, or 900 μg)
Number of subjects: 45
Study 25012727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular pasireotide long-acting release (20, 40, or 60 mg)
Number of subjects: 45
Study 25012727 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous pasireotide
Number of subjects: 45
Study 25012727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular pasireotide long-acting release
Number of subjects: 45
Study 21296033 — intervention group
Group type: EXPERIMENTAL
Intervention: SITU-LRYGB
Number of subjects: 140
Study 21296033 — intervention group
Group type: COMPARATOR
Intervention: 5-port LRYGB
Number of subjects: 140
Study 20142215 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic CoreValve (MCV)
Number of subjects: 45
Study 20142215 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN (ES)
Number of subjects: 45
Study 20142215 — intervention group
Group type: COMPARATOR
Intervention: Both MCV and ES
Number of subjects: 45
Study 17143047 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin K intake of more than 250 microg/day
Number of subjects: 0
Study 17143047 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% decrease in vitamin K intake
Number of subjects: 0
Study 17143047 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in dietary vitamin K intake by 100 microg
Number of subjects: 0
Study 17143047 — intervention group
Group type: EXPERIMENTAL
Intervention: Over-the-counter multivitamin supplements containing vitamin K1
Number of subjects: 0
Study 16274381 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg 17‐beta estradiol for 36 months
Number of subjects: 167
Study 16274381 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 36 months
Number of subjects: 167
Study 12018742 — intervention group
Group type: EXPERIMENTAL
Intervention: High Dose Therapy (HDT)
Number of subjects: 0
Study 12018742 — intervention group
Group type: COMPARATOR
Intervention: Conventional Chemotherapy (CCT)
Number of subjects: 0
Study 10789356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 54
Study 10789356 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal exposure
Number of subjects: 54
Study 10789356 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 7587973 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDADIS alcohol module
Number of subjects: 0
Study 7587973 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDADIS drug module
Number of subjects: 0
Study 7587973 — intervention group
Group type: EXPERIMENTAL
Intervention: AUDADIS diagnoses
Number of subjects: 0
Study 2078484 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of CMF until progression (A)
Number of subjects: 198
Study 2078484 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensification-discontinuation arm (B)
Number of subjects: 198
Study 447898 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beverages
Number of subjects: 72
Study 447898 — intervention group
Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 72
Study 447898 — intervention group
Group type: COMPARATOR
Intervention: No beverages
Number of subjects: 72
Study 29749718 — intervention group
Group type: EXPERIMENTAL
Intervention: Test acetaminophen product available in Mexico
Number of subjects: 28
Study 29749718 — intervention group
Group type: COMPARATOR
Intervention: Reference 500‐mg acetaminophen product
Number of subjects: 28
Study 29749718 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 28
Study 28600815 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral zone (NZ) mandibular dentures
Number of subjects: 35
Study 28600815 — intervention group
Group type: COMPARATOR
Intervention: Conventional (CV) mandibular dentures
Number of subjects: 35
Study 24728665 — intervention group
Group type: EXPERIMENTAL
Intervention: Peretinoin 600 mg/day
Number of subjects: 377
Study 24728665 — intervention group
Group type: EXPERIMENTAL
Intervention: Peretinoin 300 mg/day
Number of subjects: 377
Study 24728665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 377
Study 23668921 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative subacromial infusion catheter filled with 0.5% bupivacaine without epinephrine
Number of subjects: 88
Study 23668921 — intervention group
Group type: COMPARATOR
Intervention: Postoperative subacromial infusion catheter filled with saline solution
Number of subjects: 88
Study 23668921 — intervention group
Group type: COMPARATOR
Intervention: No postoperative subacromial infusion catheter
Number of subjects: 88
Study 23668921 — intervention group
Group type: COMPARATOR
Intervention: Mean daily oxycodone consumption
Number of subjects: 88
Study 21545606 — intervention group
Group type: EXPERIMENTAL
Intervention: A3309 (0.1-10 mg/day)
Number of subjects: 30
Study 21545606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 19644896 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 256
Study 19644896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study 17380548 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch (HES) 200/0.62 kDa
Number of subjects: 62
Study 17380548 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% Hydroxyethyl starch (HES) 130/0.4 kDa
Number of subjects: 62
Study 17380548 — intervention group
Group type: COMPARATOR
Intervention: 4% Gelatine
Number of subjects: 62
Study 15500197 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetylsalicylic acid (ASA) + 60 mg pseudoephedrine (PSE)
Number of subjects: 643
Study 15500197 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg ASA + 30 mg PSE
Number of subjects: 643
Study 15500197 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg paracetamol + 60 mg PSE (active control)
Number of subjects: 643
Study 15500197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 643
Study 11222797 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on trials
Number of subjects: 9144
Study 11222797 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotherapy initiation trials
Number of subjects: 9144
Study 9034984 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam 15 mg once daily
Number of subjects: 468
Study 9034984 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam 7.5 mg once daily
Number of subjects: 468
Study 9034984 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 468
Study 9034984 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg
Number of subjects: 468
Study 9034984 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg
Number of subjects: 468
Study 7946584 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiation treatment
Number of subjects: 223
Study 7946584 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction treatment (at 8 months)
Number of subjects: 223
Study 7946584 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (after 3 months)
Number of subjects: 223
Study 7946584 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited erythema at presentation
Number of subjects: 223
Study 7946584 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete regression of inflammatory symptoms (at 8 months)
Number of subjects: 223
Study 7946584 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumour regression (at 3 months)
Number of subjects: 223
Study 3228991 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic mixture of local anaesthetics (EMLA)
Number of subjects: 15
Study 3228991 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 15
Study 30678556 — intervention group
Group type: EXPERIMENTAL
Intervention: High-ending tune (L*+H L‐!H%)
Number of subjects: 4
Study 30678556 — intervention group
Group type: COMPARATOR
Intervention: Flat-ending tune (L+H* L‐L%)
Number of subjects: 4
Study 30678556 — intervention group
Group type: EXPERIMENTAL
Intervention: High-ending questions
Number of subjects: 4
Study 31793485 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine based (Consepsis)
Number of subjects: 120
Study 31793485 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ppm ozonated water (TeknO3zone)
Number of subjects: 120
Study 31793485 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% boric acid (Handmade)
Number of subjects: 120
Study 31793485 — intervention group
Group type: COMPARATOR
Intervention: Control (no disinfectant)
Number of subjects: 120
Study 28808915 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole tablets
Number of subjects: 100
Study 25760679 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (100 μg + 0.5 μg kg(‐1) min(‐1))
Number of subjects: 60
Study 23796191 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care intervention (20-minute session of behavioural change counselling, with potential referral to motivational enhancement therapy and local specialist alcohol services)
Number of subjects: 529
Study 23796191 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care intervention
Number of subjects: 529
Study 23796191 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (5-minute brief advice intervention)
Number of subjects: 529
Study 23796191 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 529
Study 21362268 — intervention group
Group type: EXPERIMENTAL
Intervention: Minichromosome maintenance complex component 2 (MCM2)
Number of subjects: 790
Study 21362268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclin A
Number of subjects: 790
Study 21362268 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatch repair deficiency
Number of subjects: 790
Study 21362268 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforming growth factor β receptor type II (TGFBRII) overexpression
Number of subjects: 790
Study 20205022 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Exercise (PE)
Number of subjects: 65
Study 20205022 — intervention group
Group type: COMPARATOR
Intervention: Reading a Newspaper (RN)
Number of subjects: 65
Study 17892984 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 975
Study 17892984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 975
Study 15277959 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS-R
Number of subjects: 13
Study 15277959 — intervention group
Group type: COMPARATOR
Intervention: Conventional TENS
Number of subjects: 13
Study 15277959 — intervention group
Group type: EXPERIMENTAL
Intervention: Placement of TENS electrodes on the back
Number of subjects: 13
Study 15277959 — intervention group
Group type: COMPARATOR
Intervention: Placement of TENS electrodes on the legs
Number of subjects: 13
Study 11210993 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin plus bedtime subcutaneous ultralente insulin injection
Number of subjects: 73
Study 11210993 — intervention group
Group type: COMPARATOR
Intervention: Usual insulin regimen of two to three injections per day
Number of subjects: 73
Study 11210993 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin
Number of subjects: 73
Study 9701387 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1000 mg 3 times per day)
Number of subjects: 21
Study 8027275 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (twice a day for 15 days)
Number of subjects: 90
Study 8027275 — intervention group
Group type: COMPARATOR
Intervention: Triptorelin (3.75 mg single dose 15 days before stimulation)
Number of subjects: 90
Study 8027275 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (0.1 mg daily for 4 weeks before stimulation)
Number of subjects: 90
Study 8027275 — intervention group
Group type: EXPERIMENTAL
Intervention: All protocols (A, B, C)
Number of subjects: 90
Study 2563730 — intervention group
Group type: EXPERIMENTAL
Intervention: BIM 23014 (500 micrograms, sc)
Number of subjects: 16
Study 2563730 — intervention group
Group type: EXPERIMENTAL
Intervention: BIM 23014 (250 micrograms, sc)
Number of subjects: 16
Study 2563730 — intervention group
Group type: EXPERIMENTAL
Intervention: BIM 23014 (125 micrograms, sc)
Number of subjects: 16
Study 2563730 — intervention group
Group type: EXPERIMENTAL
Intervention: BIM 23014 (2 mg/12 h, constant sc infusion)
Number of subjects: 16
Study 2563730 — intervention group
Group type: EXPERIMENTAL
Intervention: BIM 23014 (2 mg/12 h, constant sc infusion) with GHRH (10 ng/kg.min iv)
Number of subjects: 16
Study 5039779 — intervention group
Group type: EXPERIMENTAL
Intervention: Review at a preadmission clinic
Number of subjects: 99
Study 5039779 — intervention group
Group type: COMPARATOR
Intervention: Direct admission to a hospital bed
Number of subjects: 99
Study 29304831 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video plus telecare (protocol-guided follow-up telephone call)
Number of subjects: 75
Study 29304831 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video only
Number of subjects: 75
Study 29304831 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 75